Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells
Sean A. Misek, Patrick Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I. Doseff, Bin Chen, Kathleen A. Gallo, Richard R. Neubig
Topics & Concepts
IbrutinibMelanomaCancer researchChemistryMedicinePharmacologyInternal medicineLeukemiaChronic lymphocytic leukemiaMelanoma and MAPK PathwaysHippo pathway signaling and YAP/TAZPI3K/AKT/mTOR signaling in cancer